Cellectar Bio's Iopofosine Data Shows Favorable Safety Profile In Head & Neck Cancer

Cellectar Biosciences Inc CLRB has completed part A portion of a safety and tolerability study of iopofosine I-131 (iopofosine) in combination with external beam radiation (EBRT) in relapsed or refractory head and neck cancer.
Related: Cellectar Receives $2M NIH Grant For Rare Lymphoma Study.
The reduction in the amount or fractions (doses) of EBRT can potentially diminish the (number and severity of) adverse events associated with EBRT.
Patients with head and neck cancer typically receive approximately 60-70 Grays (Gy) of EBRT given as 2 – 3 Gy daily doses over a six-week timeframe.
Part B of the study will further assess the safety and potential benefits of iopofosine in combination with EBRT in a cohort of up to 24 patients.
Read Next: Cellectar, LegoChemBio Team Up To Develop Phospholipid Drug Conjugates For Solid Tumors.
Price Action: CLRB stock is up 2.58% at $0.98 during the market session on the last check Wednesday.